3rd Nov 2009 13:45
Abcam plc ("Abcam" or "the Company")
Director Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that it was notified on 2 November 2009 that Tim Dye, a non-executive director of the Company, bought 2,500 ordinary shares of 1 pence each in the Company on 2 November 2009 at a price of 941p per ordinary share. Following this transaction Mr Dye has an interest in 2,500 ordinary shares of 1 pence each in the Company.
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade / Nick Westlake, Nominated Adviser |
|
|
James Black, Corporate Broking |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Mary-Jane Johnson / Stasa Filiplic |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its three operating companies.
Related Shares:
ABC.L